The abstract is read at the publisher; the summary is JClub's.
Stem cell-derived extracellular vesicle products face regulatory hurdles due to complex manufacturing, molecular heterogeneity, and diversified mechanisms of action, complicating evaluation and approval.
- Why it matters: Regulatory translation is challenging because EV variability makes it difficult to define consistent quality attributes and assess safety and efficacy under drug review standards.
- What they did: This review outlines Chemistry, Manufacturing, and Control (CMC) considerations for IND submissions, covering cell substrate and raw material establishment, process development, viral safety, quality characterization, specification setting, stability, and comparability studies.
- The result: It provides an operational framework for EV developers from bench to bedside and summarizes EV product development landscapes in China and globally, highlighting standardization difficulties and translational hurdles.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.